Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety evaluation of cancer-specific PET probe F18-NKO-035 in healthy male adults
jRCTs051190057Phase 1Completed
- Sponsor
- J-Pharma
- Start
- Nov 2019
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of F18-NKO-035, sponsored by J-Pharma. Primary endpoint: Whole-body effective radiation dose. Started Nov 2019; status: completed.
02
Drugs
F18-NKO-035
Beyond the preview
Go deeper on jRCTs051190057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051190057.